On February 19, 2020, the clinical trial application for "Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection" jointly submitted by Lijun Biopharmaceutical and Xinkanghe Biotech was tacitly approved by the National Medical Products Administration.
Release time:
2019-02-19 13:51
On February 19, 2020, the clinical trial application for "Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection" jointly submitted by Lijun Biopharmaceutical and Xinkanghe Biotech was tacitly approved by the National Medical Products Administration.
Next Page
Next Page
Related News